Barcelona, Spain – Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug, TYRA-300. The drug targets changes in the FGFR3 gene that drive tumour growth in about 10%-20% of these patients....
Latest News
Alexandria, VA. Patients in the phase 3 CheckMate-649 trial (NCT02872116) who received nivolumab (Opdivo) plus chemotherapy reported stable or better on-treatment health-related quality of life (HRQOL) compared with chemotherapy alone. CheckMate-649 included patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma, and findings were published in...
Philadelphia, Pennsylvania – The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with immune checkpoint inhibitors (ICIs) had no disease progression two years after discontinuing treatment. ICIs have proven effective against certain solid tumors, including those with a high microsatellite instability (MSI-H) or...
When the daughter of Hyderabad resident Rahul Vipparathi was diagnosed with Tuberous Sclerosis Complex (TSC), a rare genetic disorder causing the growth of numerous benign tumours, it felt like his entire world had come crashing down. As a parent, one is expected to be the anchor during a storm, but...
CAMBRIDGE, Mass. — PatientsLikeMe, the first community-based personalized medicine platform for people with life-changing conditions, and 23andMe, the world’s leading personal genomics company, announce a partnership today to help people with Parkinson’s disease. PatientsLikeMe is teaming with 23andMe on its effort to recruit 10,000 people with Parkinson’s for a massive...
Aargau, Switzerland – In the treatment of cancer patients, irradiation can be adapted anew each day to the position of the tumour and conditions in the body. Researchers at the Paul Scherrer Institute PSI have now, for the first time, integrated such a workflow into everyday clinical practice in proton...
Oslo, Norway – PCI Biotech Holding ASA (OSE: PCIB), a cancer-focused biopharmaceutical company with a unique intracellular delivery technology via Photochemical Internalisation and Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, announced today an extension of their current collaboration. The companies jointly research...
Oslo – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug Designation to its lead product candidate, fimaporfin, for combination treatment with gemcitabine in patients with inoperable locally advanced or metastatic bile...
Oslo (Norway) – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that the first US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients. The RELEASE study...
WASHINGTON – Patients, clinicians and families facing uncertainty about their choices for managing Type 2 diabetes and rare diseases will gain new evidence to inform their decision making from comparative clinical effectiveness research (CER) studies that the Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved for a total...